( February 27, 2026, 10:17 AM EST) -- WASHINGTON, D.C. — The United States government on Feb. 25 filed a motion to participate in oral arguments before the U.S. Supreme Court when it considers arguments from a bioequivalent pharmaceutical maker that a patent holder’s complaint failed to state a claim for induced infringement because the “skinny label” generic version of the patent carved out the patented cardiovascular use of the drug; the government’s motion was filed a day after it filed an amicus curiae brief in support of the petitioner entity....